Advisornet Financial’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-25
Closed -$87 – 2277
2025
Q3
$87 Sell
25
-25
-50% -$70 ﹤0.01% 2193
2025
Q2
$110 Sell
50
-100
-67% -$164 ﹤0.01% 2171
2025
Q1
$174 Hold
150
– – ﹤0.01% 2084
2024
Q4
$191 Sell
150
-405
-73% -$1.03K ﹤0.01% 1885
2024
Q3
$1.89K Hold
555
– – ﹤0.01% 1767
2024
Q2
$2.59K Hold
555
– – ﹤0.01% 1582
2024
Q1
$4.12K Buy
555
+460
+484% +$3.82K ﹤0.01% 1476
2023
Q4
$962 Hold
95
– – ﹤0.01% 1899
2023
Q3
$741 Hold
95
– – ﹤0.01% 1876
2023
Q2
$782 Hold
95
– – ﹤0.01% 1941
2023
Q1
$689 Hold
95
– – ﹤0.01% 1991
2022
Q4
$843 Hold
95
– – ﹤0.01% 1887
2022
Q3
$1K Sell
95
-450
-83% -$7.01K ﹤0.01% 1757
2022
Q2
$6K Buy
545
+130
+31% +$1.74K ﹤0.01% 1461
2022
Q1
$8K Hold
415
– – ﹤0.01% 1491
2021
Q4
$11K Hold
415
– – ﹤0.01% 1452
2021
Q3
$17K Buy
415
+385
+1,283% +$21.1K ﹤0.01% 1294
2021
Q2
$2K Hold
30
– – ﹤0.01% 1677
2021
Q1
$1K Buy
+30
New +$1.71K ﹤0.01% 1683
2019
Q2
– Sell
-150
Closed -$4K – 1706
2019
Q1
$4K Hold
150
– – ﹤0.01% 1349
2018
Q4
$3K Hold
150
– – ﹤0.01% 1302
2018
Q3
$5K Hold
150
– – ﹤0.01% 1273
2018
Q2
$5K Buy
+150
New +$5.31K ﹤0.01% 1275

Other funds holding EDIT

Advisornet Financial's EDIT Position: Q4 2025 in Review

Advisornet Financial sold out of Editas Medicine (EDIT) in Q4 2025, closing a stake of 25 shares — an estimated $87 sold.

Advisornet Financial first reported a position in EDIT in Q2 2018 and held it in 23 quarters. The position peaked at $17K in Q3 2021. 197 funds tracked by Wall St. Rank hold EDIT as of Q4 2025.

  • Advisornet Financial reported no remaining Editas Medicine position as of Q4 2025 after selling out during the quarter.
  • Advisornet Financial sold 25 Editas Medicine shares in Q4 2025, an estimated $87.
  • Advisornet Financial first reported a position in Editas Medicine in Q2 2018 and held it in 23 quarters.
  • Advisornet Financial's Editas Medicine position peaked at $17K in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2025.

Based on Advisornet Financial's 13F filing for Q4 2025, filed 20 Jan 2026.